Nxera Pharma’s Schizophrenia Treatment Enters Phase 3 Trials

An update from Sosei Group ( (JP:4565) ) is now available.

Nxera Pharma announced that its partner, Neurocrine Biosciences, has initiated a Phase 3 trial for NBI-1117568, an investigational treatment for schizophrenia. This marks a significant milestone as it is the first NxWave™-designed molecule to reach this stage, potentially enhancing Nxera’s position in the neuropsychiatric treatment market. The trial will assess the drug’s efficacy, safety, and tolerability, with the potential to offer a novel mechanism for treating schizophrenia without the need for combination therapy, which could have significant implications for stakeholders.

More about Sosei Group

Nxera Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on the development of innovative treatments for neuropsychiatric disorders. The company collaborates with Neurocrine Biosciences to advance a portfolio of muscarinic agonists, designed using its NxWave™ platform, to address unmet needs in this field.

YTD Price Performance: -5.15%

Average Trading Volume: 400

Technical Sentiment Signal: Buy

Current Market Cap: $561.2M

See more insights into 4565 stock on TipRanks’ Stock Analysis page.